At Isopogen we believe cellular medicine has the power to change lives. Our proprietary StemSmart treatment is the subject of 10 clinical trials, with 170 patients already safely treated.

Our advanced pipeline of research spans a number of conditions with impressive results including a 78% clinical response and 53% clinical remission in life-threatening (refractory) Crohn’s patients.

As the only company to show clinical efficacy of Mesenchymal Stem Cells (MSC) in Crohn’s sufferers (Phase II clinical trial), we are now focused on completing late-stage clinical development for life-threatening (refractory) Crohn’s disease, and initiating Phase II clinical trials for non-life-threatening Crohn’s Disease. Together, these conditions represent a market of 2 million sufferers worldwide.

Isopogen has also conducted clinical trials on other disorders with our Stemsmart technology. These disorders include Kidney Transplant Rejection, Chronic Lung Allograft Dysfunction, and Graft versus Host Disease (GvHD). These Phase 1 trials have demonstrated the safety, and in some cases, the efficacy of our MSC’s.